Introduction

Exploring the pivotal ATTR Act Trial and the effectiveness of Tafamidis in stabilizing Transthyretin protein to prevent amyloid-fibril formation, leading to improved outcomes for patients with Trans-Thyretin Cardiomyopathy.

Transcript

Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app